Umeå universitets logga

umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Efficacy and safety of transscleral cyclophotocoagulation in Swedish glaucoma patients
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Oftalmiatrik.ORCID-id: 0000-0002-4102-2455
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Oftalmiatrik.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Oftalmiatrik.
Umeå universitet, Medicinska fakulteten, Institutionen för klinisk vetenskap, Oftalmiatrik. Umeå universitet, Medicinska fakulteten, Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM).ORCID-id: 0000-0003-0218-4563
2019 (Engelska)Ingår i: Acta Ophthalmologica, ISSN 1755-375X, E-ISSN 1755-3768, Vol. 97, nr 8, s. 764-770Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Purpose: To retrospectively evaluate the efficacy and safety of all transscleral cyclophotocoagulation (TCP) treatments performed during a 5-year period.

Methods: Medical records of all patients, who had undergone TCP treatment between 2010 and 2014 at Umea University Hospital, Sweden, were evaluated. Clinical data including intraocular pressure (IOP), visual acuity (VA), number of topical glaucoma medications, use of oral acetazolamide, retreatments and complications during a 2-year follow-up were registered. Global success was defined as IOP 6-18 mmHg with or without glaucoma medication. 

Results: Three hundred patients underwent TCP during the time period. Mean IOP at baseline was 29.3 11.0 (mean +/- standard deviation) mmHg (n = 297) with a mean reduction of 11.5 (+/- 12.0) mmHg at 1 year (n = 258; p < 0.001) and 12.6 (<plus/minus>12.0) mmHg at 2-year follow-up (n = 245; p < 0.001). Global success at 2 years was 64%, achieved by a mean of 1.2 treatments (n = 257). The number of topical glaucoma medications at baseline was 3.1 (<plus/minus>1.0; n = 296) and was reduced by 0.9 (+/- 1.0) medications at 2 years (n = 244; p < 0.001). Use of oral acetazolamide decreased from 30% (n = 90) at baseline to 5.3% (n = 13) at 2 years. In eyes with Snellen VA <greater than or equal to> 0.1, the mean VA at baseline was 0.55 (+/- 0.3) logarithm of the minimum angle of resolution (logMAR; n = 132) and 1.1 (+/- 0.9) logMAR (n = 76) at 2 years (p < 0.001). No cases of phthisis bulbi were found.

Conclusion: This study displays a substantial and long-term reduction of IOP following TCP with a decrease in topical and oral glaucoma medications. The treatment appears to be safe but the decrease in VA during follow-up is a concern that needs further evaluation.

Ort, förlag, år, upplaga, sidor
John Wiley & Sons, 2019. Vol. 97, nr 8, s. 764-770
Nyckelord [en]
intraocular pressure, laser treatment, open-angle glaucoma, pseudoexfoliation glaucoma, transscleral cyclophotocoagulation
Nationell ämneskategori
Oftalmologi
Identifikatorer
URN: urn:nbn:se:umu:diva-166383DOI: 10.1111/aos.14125ISI: 000496591800005PubMedID: 31025793Scopus ID: 2-s2.0-85065020711OAI: oai:DiVA.org:umu-166383DiVA, id: diva2:1380289
Tillgänglig från: 2019-12-18 Skapad: 2019-12-18 Senast uppdaterad: 2024-01-15Bibliografiskt granskad
Ingår i avhandling
1. Laser treatment in glaucoma: efficacy and safety
Öppna denna publikation i ny flik eller fönster >>Laser treatment in glaucoma: efficacy and safety
2023 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Abstract [en]

Glaucoma is a progressive optic neuropathy and the major cause of irreversible blindness worldwide. Although the pathogenesis of glaucoma is not completely understood, the most important risk factor for development and progression of the disease is an elevated intraocular pressure (IOP). Current glaucoma treatment aims to reduce the IOP in the affected eye. This can be achieved by topical drops, laser therapy or surgery. Laser treatment is used at different stages of the glaucoma disease. Some types of laser procedures are used as first-line treatments or as complement to topical medications or surgery, while other types are used in advanced glaucoma as a last option when other therapies have failed. Although laser therapy has long been used to reduce the IOP in glaucoma, knowledge gaps remain. The aim of this thesis was to evaluate the efficacy and safety, in both a short- and long-term perspective, of two of the most frequently used laser procedures in glaucoma: laser trabeculoplasty (LTP) and transscleral cyclophotocoagulation (TCP).

In the first study, a retrospective analysis, the long-term efficacy and safety of TCP was evaluated in 300 eyes of 300 glaucoma patients in northern Sweden. We found an overall substantial IOP reduction of more than 10 mmHg that was maintained at least 2 years in various types of glaucoma. Following TCP, the patients could reduce their treatment with an average of one substance of topical glaucoma medication in the treated eye. No case of phthisis bulbi, the most feared complication of TCP, was reported. However, a general decline in visual acuity (VA) was noted during the two-year follow up period, and the cause of this finding was difficult to assess due to the retrospective nature of the study.

The short-term effect of TCP on IOP was further investigated in a prospective study of 58 eyes of 58 glaucoma patients. IOP was measured at baseline before TCP and at five additional time-points up to 24 hours after the treatment. The VA was measured before TCP and at the 24 h examination. The results showed a transient IOP spike with a peak at six hours after TCP in approximately 40% of the eyes. Spikes were more common in eyes with pseudoexfoliation glaucoma.

The last two studies of the thesis focused on the short- and long-term efficacy of LTP. One-hundred fifty-two eyes of 122 newly diagnosed glaucoma patients that had been randomized to the multi-treated arm in the Glaucoma Intensive Treatment Study (GITS) were included. All studied eyes were treated with three different IOP-lowering substances and after one week, LTP was performed. We demonstrated that there was an additional IOP-lowering effect of LTP but that this effect was strongly associated with the level of IOP before the laser, where a higher IOP pre-LTP yielded a greater IOP reduction. Eyes with pre-laser IOP ³15 mmHg showed a significant IOP reduction that was maintained during four years of follow-up. However, in eyes with pre-LTP IOP <15 mmHg, the effect of laser treatment was limited.

In summary, this thesis investigated the efficacy and safety of TCP both retrospectively in a longer perspective and prospectively during the first 24 hours after treatment. An overall high efficacy without serious complications was shown, but a possible decline in VA must be considered in the long run. Furthermore, the risk of IOP spikes after TCP implies that additional IOP-lowering treatment should be considered during the first 24 hours, especially in eyes with pseudoexfoliation glaucoma or severe glaucoma damage. Finally, LTP may provide a valuable long-lasting IOP-lowering effect despite medical multi-treatment in eyes with a pre-LTP IOP ³15 mmHg.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå Universitet, 2023. s. 60
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 2239
Nyckelord
glaucoma, laser treatment, intraocular pressure, glaucoma treatment, glaukom, laserbehandling, ögontryck, glaukombehandling
Nationell ämneskategori
Oftalmologi
Forskningsämne
oftalmiatrik; oftalmiatrik
Identifikatorer
urn:nbn:se:umu:diva-206004 (URN)978-91-8070-013-9 (ISBN)978-91-8070-012-2 (ISBN)
Disputation
2023-04-21, Umeälven, Målpunkt ZA-21, Psykiatrihuset, NUS, Umeå, 09:00 (Svenska)
Opponent
Handledare
Forskningsfinansiär
Umeå universitetKronprinsessan Margaretas MinnesfondÖgonfonden
Tillgänglig från: 2023-03-31 Skapad: 2023-03-27 Senast uppdaterad: 2023-03-28Bibliografiskt granskad

Open Access i DiVA

Fulltext saknas i DiVA

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Rasmuson, ErikaLindén, ChristinaLundberg, BjörnJóhannesson, Gauti

Sök vidare i DiVA

Av författaren/redaktören
Rasmuson, ErikaLindén, ChristinaLundberg, BjörnJóhannesson, Gauti
Av organisationen
OftalmiatrikWallenberg centrum för molekylär medicin vid Umeå universitet (WCMM)
I samma tidskrift
Acta Ophthalmologica
Oftalmologi

Sök vidare utanför DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 490 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf